SAN FRANCISCO — Sidley Austin has snagged a life sciences partner from O’Melveny & Myers for its Palo Alto office.
George Samuel “Sam” Zucker joined Sidley’s life sciences and corporate emerging companies and venture capital practice groups as a partner on Monday. For 11 years, he split his time between O’Melveny’s Silicon Valley and New York offices.
Zucker concentrates on corporate transactions for health-care, life sciences and technology companies and their investors, such as venture capital firm Venrock. Prior to joining O’Melveny in 2003, Zucker spent almost two years with the now-defunct Brobeck, Phleger & Harrison. He began his legal career as an associate at Wilson Sonsini Goodrich & Rosati in 1997.
He said he was drawn to Sidley Austin’s “very strong collaborative culture that integrates offices around the world.”
With regulatory attorneys in the U.S., Europe and China, Sidley Austin is “the only firm in the world that can do leading regulatory on three continents,” he said. “I look forward to working with people who have expertise that I don’t have and providing greater value to clients than I was able to before.”
Earlier this year, Zucker represented Boston-based Dicerna Pharmaceuticals in its initial public offering and San Francisco’s Nektar Therapeutics in its $130 million follow-on offering. He also advised a company on the acquisition of a commercial stage drug from a large pharmaceutical company, he said.
Thomas DeFilipps, managing partner of the firm’s Palo Alto office, said Zucker’s “mix of transactional skills and sector-based knowledge” will enhance the firm’s offerings. Of the 39 attorneys based in Palo Alto, seven are focused on the life sciences industry.
Contact the reporter at firstname.lastname@example.org.